Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Analysis of Immune Cells Predicts Breast Cancer Prognosis

By LabMedica International staff writers
Posted on 20 Nov 2024

Tumor-infiltrating lymphocytes (TILs) are immune cells crucial in combating cancer. More...

Their presence in a tumor indicates that the immune system is attempting to attack and eliminate cancer cells. TILs can be important indicators in predicting how patients with triple-negative breast cancer will respond to treatment and how the disease might progress. However, assessing these immune cells can yield inconsistent results. Artificial intelligence (AI) has the potential to standardize and automate this process, but proving its effectiveness for healthcare use has been challenging. Now, researchers have explored how different AI models can predict the prognosis of triple-negative breast cancer by analyzing specific immune cells within the tumor. This study, published in eClinicalMedicine, represents a significant step toward incorporating AI into cancer care to enhance patient outcomes.

Researchers at Karolinska Institutet (Stockholm, Sweden) tested ten different AI models to evaluate their ability to analyze tumor-infiltrating lymphocytes in tissue samples from patients with triple-negative breast cancer. The results revealed that the performance of the AI models varied, but eight out of the ten models demonstrated strong prognostic capability, meaning they could predict patient health outcomes with similar accuracy. Even models trained on smaller datasets showed promising results, suggesting that tumor-infiltrating lymphocytes are a reliable biomarker. The study highlights the need for large datasets to compare different AI models and validate their effectiveness before they can be used in clinical practice. Although the findings are promising, further validation is required.

“Our research highlights the importance of independent studies that mimic real clinical practice,” said Balazs Acs, researcher at the Department of Oncology-Pathology, Karolinska Institutet. “Only through such testing can we ensure that AI tools are reliable and effective for clinical use.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.